1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Dexcom G6 Finally Gets Official Classification

 
• By Brian Bossetta

After nearly four years of treating the Dexcom glucose monitoring system as moderate-risk class II, the US FDA made the designation official.

DEXCOM G6
• Source: Alamy

The US Food and Drug Administration has officially granted a request from DexCom Inc. to designate its G6 continuous glucose monitoring (CGM) system as moderate-risk class II.

The FDA first received the request from the company to grant de novo classification to the Dexcom G6 in 2017,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

NextGen Dx Panel Expects Continued Limbo On LDT Regulation

 
• By Elizabeth Orr

A recent conference panel discussed the stagnation in diagnostics regulation, highlighting the FDA's failed regulatory efforts on lab-developed tests. Political and legislative challenges hinder other reforms, and concerns over Medicare reimbursement cuts loom for the clinical lab industry.

Medtech Must Address AI Risks Now Or Jeopardize Its Future Potential, Expert Warns

 
• By Amanda Maxwell

Urgent action is needed to address gaps in how risks from medical devices and diagnostics utilizing AI are identified, mitigated and managed. So says James Pink, renowned medtech regulatory expert in an interview with Medtech Insight.

No EUDAMED, No Market: ‘Waiting Until Mandatory Deadline Is Risky’

 
• By Natasha Barrow

EirMed CEO Richard Houlihan warns that EUDAMED (the European database on medical devices) publication delays may harm medical device manufacturers. Currently, only a fraction of the required uploads have occurred, creating potential compliance risks as the mandatory deadline approaches.

Medical Device Recalls Down In Q1 For Lowest Quarterly Count In 3 Years. But Will It Last?

 
• By Brian Bossetta

Despite a surge in product recalls across five key industries in the first quarter of the year, medical device recalls were down, according to Sedgwick’s latest recall index. But the firm noted they’ve since ticked up.

More from Policy & Regulation

Exercise Caution While Using Hyperbaric Oxygen Therapy Devices, FDA Warns

 
• By Brian Bossetta

The US FDA has published a list of recommendations for the safe use of hyperbaric oxygen therapy devices. While the therapy can be effective in treating several conditions, the agency says providers need to understand its potential risks.

Germany Readies For Its EPR October Revolution

 
• By Ashley Yeo

Germany’s electronic patient record – ePA – is a flagship initiative of the ongoing national healthcare reform. The medtech industry welcomes rollout of the ePA while calling for further improvements.

No EUDAMED, No Market: ‘Waiting Until Mandatory Deadline Is Risky’

 
• By Natasha Barrow

EirMed CEO Richard Houlihan warns that EUDAMED (the European database on medical devices) publication delays may harm medical device manufacturers. Currently, only a fraction of the required uploads have occurred, creating potential compliance risks as the mandatory deadline approaches.